![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
基于抗体和细胞治疗先进的巨细胞瘤:既定和新概念
Peter Valent1,2, Cem Akin3, Michel Arock4
1Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.
International journal of molecular sciences
|October 28, 2023
概括
先进的全身性巨细胞瘤 (SM) 是一种罕见的癌症. 本综述涵盖了耐药性MS的治疗方法,包括向疗法和干细胞移植.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 先进的全身性乳腺细胞瘤 (SM) 涉及不受控制的乳腺细胞生长,导致器官损伤和不良预后.
- 关键的遗传驱动因素包括KIT突变 (例如D816V) 和其他突变,如SRSF2,ASXL1或RUNX1,特别是在SM与相关的血液瘤 (SM-AHN).
- 虽然治疗改善了生存率,但耐药性和复发仍然是重大挑战.
研究的目的:
- 审查当前和新兴的治疗选择,以治疗耐药的先进系统性乳腺细胞瘤的患者.
- 讨论管理复发性或耐药性疾病的策略,包括新的向疗法和干细胞根除治疗.
主要方法:
- 关于先进的全身性巨细胞瘤治疗的文献综述.
- 讨论针对KIT的新型药物,基于抗体的疗法和全原干细胞移植.
- 重点关注耐药性和多变异性MS的治疗策略.
主要成果:
- 新型KIT抑制剂显示有前途,但并不能在所有患者中实现缓解.
- 复发性疾病可能是多变异的,KIT D816V阴性,表现出多种药物耐药性.
- 化学疗法,抗体治疗和干细胞移植等替代疗法对于耐火病例至关重要.
结论:
- 有效管理先进的SM,特别是耐药的形式,需要一个多方面的方法.
- 对新型疗法的持续研究对于改善先进的全身性乳腺细胞瘤的结果至关重要.
- 同源干细胞移植仍然是符合条件的高级耐火性MS患者的关键选择.
更多相关视频
09:54Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
3.6K
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
2.7K
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
312
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
312
01:27Tumor Immunotherapy
538
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
538
01:31Hybridoma Technology
14.8K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.8K